Organ-protective therapy with sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) is recommended for people with type 2 diabetes (PwT2D) and cardiorenal comorbidities, yet real-world uptake remains uncertain. Here, SLC5A2 is linked to type 2 diabetes mellitus.